Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?
There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data s...
Saved in:
Main Authors: | Jacob W. Bruinius, Karl J. Dykema, Sabrina L. Noyes, Bin Tean Teh, Brian R. Lane |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Urology |
Online Access: | http://dx.doi.org/10.1155/2019/2479823 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01) -
The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice
by: Christina Hui Lee Ng, et al.
Published: (2023-01-01) -
Automated and Reproducible Detection of Vascular Endothelial Growth Factor (VEGF) in Renal Tissue Sections
by: Nayana Damiani Macedo, et al.
Published: (2019-01-01) -
Association of vascular endothelial growth factor B (VEGFВ) gene polymorphisms with intracranial aneurysms
by: R. I. Sultanova, et al.
Published: (2019-01-01) -
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
by: Kenichi Kimoto, et al.
Published: (2012-01-01)